CLINICAL REVIEW Executive Summary Section Clinical Review for NDA[removed]Supplement SE8-019

First Page		Document Content
Chemistry Irinotecan Neuroblastoma Carboplatin Medulloblastoma Chemotherapy regimens Glioblastoma multiforme Atypical teratoid rhabdoid tumor Bevacizumab Medicine Brain tumor Oncology		CLINICAL REVIEW Executive Summary Section Clinical Review for NDA[removed]Supplement SE8-019 Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 717,51 KB Share Document on Facebook

	United States Government Accountability Office GAO Report to the Ranking Member, Committee on Finance, U.S. Senate DocID: 1riEa - View Document
	Lettre d’information du réseau GCO - Spéciale ASCOLes Groupes Coopérateurs en Oncologie à l’ASCO 2016 Les Groupes Coopérateurs en Oncologie (GCO) seront représentés au 52ème congrès de l’ASCO (Ameri DocID: 1qX2r - View Document
	References [1] R. A. Adams, A. M. Meade, A. Madi, D. Fisher, E. Kay, S. Kenny, R. S. Kaplan, and T. S. Maughan. Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC DocID: 1qSc2 - View Document
	CURRICULUM VITAE Mary W. Redman, Ph.D. Current Address: DocID: 1qCPH - View Document
	CABARET: Carboplatin and bevacizumab in recurrent glioblastoma study (Part 1) The CABARET trial is helping researchers answer an important health question. It is providing evidence for oncologists planning treatment for DocID: 1pDeC - View Document